A phase lllb, open.label study of afatinib in EGFR TKI-naive
patients with EGFR mutation-positive NSCLC: A biomarker
analysis

Skip to top bar Skip to header Skip to content Skip to footer

Publications Detailed Information on Publication Record

Detailed Information on Publication Record

a 2019

A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis

ROSSEL, R., M. POLTORATSKIY, M. HOCHAMIR, K.K. LAKTINOV, R. RAMLAU et. al.

Basic information

Original name

A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis

Authors

ROSSEL, R., M. POLTORATSKIY, M. HOCHAMIR, K.K. LAKTINOV, R. RAMLAU, M. ALONSO, S. GARCIA, Jana SKŘIČKOVÁ, P.L. PIOVANO, S. RIZZATO, P. BIDOLI, D. KOWALSKI, L. CLEMENTI, A. CSECH and F. DE MARINIS

Edition

European Society for Medical Oncology - ESMO Asia Congress 2019, 2019

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Změněno: 11/12/2019 14:00, Kateřina Medková

ROSSEL, R., M. POLTORATSKIY, M. HOCHAMIR, K.K. LAKTINOV, R. RAMLAU, M. ALONSO, S. GARCIA, Jana SKŘIČKOVÁ, P.L. PIOVANO, S. RIZZATO, P. BIDOLI, D. KOWALSKI, L. CLEMENTI, A. CSECH and F. DE MARINIS. A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis. In European Society for Medical Oncology - ESMO Asia Congress 2019. 2019.

@proceedings{1590497,
   author = {Rossel, R. and Poltoratskiy, M. and Hochamir, M. and Laktinov, K.K. and Ramlau, R. and Alonso, M. and Garcia, S. and Skřičková, Jana and Piovano, P.L. and Rizzato, S. and Bidoli, P. and Kowalski, D. and Clementi, L. and Csech, A. and De Marinis, F.},
   booktitle = {European Society for Medical Oncology - ESMO Asia Congress 2019},
   title = {A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis},
   year = {2019}
}

TY  - CONF
ID  - 1590497
AU  - Rossel, R. - Poltoratskiy, M. - Hochamir, M. - Laktinov, K.K. - Ramlau, R. - Alonso, M. - Garcia, S. - Skřičková, Jana - Piovano, P.L. - Rizzato, S. - Bidoli, P. - Kowalski, D. - Clementi, L. - Csech, A. - De Marinis, F.
PY  - 2019
TI  - A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis
ER  -

ROSSEL, R., M. POLTORATSKIY, M. HOCHAMIR, K.K. LAKTINOV, R. RAMLAU, M. ALONSO, S. GARCIA, Jana SKŘIČKOVÁ, P.L. PIOVANO, S. RIZZATO, P. BIDOLI, D. KOWALSKI, L. CLEMENTI, A. CSECH and F. DE MARINIS. A phase lllb, open.label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis. In \textit{European Society for Medical Oncology - ESMO Asia Congress 2019}. 2019.